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Abstract
Studies on the endogenous opioid system have demonstrated its presence, including opioid receptors, not 
only in the central nervous system but also in the respiratory tract. Although dyspnoea mechanisms are not 
fully understood, the presence of these receptors, both centrally and peripherally, provides the potential 
for treatment of respiratory symptoms, such as dyspnoea and cough, with systemic and local application 
of opioids, used when causal treatment of advanced non-cancer pulmonary diseases becomes insufficient. 
While quality of research supporting the use of opioids in the treatment of cough remains low, there is  
a growing body of evidence supporting the efficacy and safety of parenteral and nebulised opioids in the 
symptomatic treatment of dyspnoea.
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Streszczenie
Badania nad endogennym układem opioidowym wykazały obecność receptorów opioidowych, nie tylko 
w ośrodkowym układzie nerwowym, ale także w drogach oddechowych. Chociaż mechanizmy duszności nie 
są w pełni zrozumiałe, obecność tych receptorów, zarówno centralnie jak i obwodowo, zapewnia możliwość 
leczenia objawów ze strony dróg oddechowych, takich jak duszność i kaszel, przy ogólnoustrojowym lub 
miejscowym zastosowaniu opioidów, kiedy leczenie przyczynowe zaawansowanych nienowotworowych 
choroby płuc jest niewystarczające. Podczas gdy jakość badań dotyczących stosowania opioidów w leczeniu 
kaszlu pozostaje niska, istnieje coraz więcej dowodów potwierdzających skuteczność i bezpieczeństwo 
parenteralnych i nebulizowanych opioidów w leczeniu duszności.
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Introduction
Palliative care aims to improve quality of life (QoL) 
of patients and their families facing life-limiting, 
progressive diseases, by preventing and alleviating 
somatic, psychological, social and spiritual issues 
through their early identification, evaluation and 
treatment. It is widely recognised as an important 
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stimuli, including acute hypercapnia, which can alter 
cerebral blood flow, meaning that their results should 
be treated with caution [11, 13]. 
It is postulated, that opioids alleviate dyspnoea 
by decreasing respiratory drive, modulating central 
dyspnoea perception, decreasing anxiety and binding 
with peripheral opioid receptors in lung [14]. Opioids 
indeed can reduce the sensitivity of the brainstem 
respiratory centres to hypercapnia and hypoxia, thus 
promoting loss of respiratory drive, what might lead 
to higher pCO2  and lower O2 levels [9]. However, as 
demonstrated in metanalyses of randomised con-
trolled trials (RCT) of opioid use in dyspnoea [15, 16], 
opioids can reduce dyspnoea in doses which do not 
cause significant changes in blood gases levels. In 
a study by Estfan et al. [17], parenteral administra-
tion of opioid for cancer pain management did not 
cause significant change in blood gas parameters or 
drop in respiratory rate (RR), except in two patients, 
out of thirty, whose RR drop was transient, did not 
cause hypoventilation and resolved spontaneously. 
However, in a study conducted by Clemens et al. [18], 
who delivered opioids to dyspnoeic palliative care 
patients, authors did observe drop in RR, following 
dyspnoea improvement after morphine application, 
which nonetheless did not change SaO2 and tcP-
CO2. The authors speculate, that it might be a result 
of a rise in tidal volume, which sustained minute 
ventilation, however, tidal volume was not measured. 
It is worth underlining, that anxiety was measured on 
numerical rating scale along with dyspnoea, and a sig-
nificant correlation between the two was observed, 
meaning that drop in RR might have been a result 
of anxiety reduction. This drop, along with other, re-
duced physiological reactions to anxiety can translate 
into reduced O2 consumption. It therefore comes as 
no surprise, because endogenous opioid system is 
essential to neural modulation of anxiety [19]. On 
the other hand, Pattinson et al. [9] emphasise, that 
even though opioids do cause reduction in hypercap-
nia ventilatory response, the change in steady-state 
pCO2 will be minor. 
Opioids are also known to reduce air hunger [13], 
by modifying mismatch between actual ventilation, 
limited by pulmonary disease, and motor drive to 
breathe, which is relayed by corollary discharge to the 
cerebral cortex. It was demonstrated in neuroimaging 
studies [14], that opioids alter cerebral blood flow in 
aforementioned brain regions, presumably engaged 
in dyspnoea processing. 
Opioid receptors can also be found in respiratory 
tract, although their local physiological role is uncer-
tain. Animal studies showed, that opioid receptors are 
distributed in respiratory tract peripherally, mainly in 
part of the comprehensive care plan for patients with 
severe lung diseases. The most common symptom in 
this group of patients, and yet most difficult to treat, 
is intensifying dyspnoea, which develops in the natu-
ral course of many respiratory diseases. Moderate to 
severe dyspnoea appearing during minimal effort is 
experienced by over 90% of patients in advanced sta-
ges of chronic obstructive pulmonary disease (COPD), 
idiopathic pulmonary fibrosis (IPF) and cystic fibrosis 
(CF) [1]. Other common respiratory symptom, someti-
mes occurring along dyspnoea, is chronic cough. Chro-
nic cough, i.e. lasting more than eight weeks, occurs 
frequently in advanced respiratory diseases [2] and has 
the ability to severely impact QoL as in IPF, where cough 
appears in 70–85% of patients, and is often severe 
enough to cause them to avoid social interactions in 
fear of incontinence, emesis or syncope [3]. It is to no 
surprise then, that patients with advanced pulmonary 
disease must be provided with a multidisciplinary care 
plan [4, 5], including effective pharmacotherapy.
Mechanism of action
To date, opioids are the only confirmed endoge-
nous neurotransmitters, which modulate dyspnoea. 
It was demonstrated in several studies, that blocking 
opioid receptors with intravenous naloxone, which 
acts both in central nervous system and peripherally, 
increases dyspnoea in COPD [6, 7] and asthma pa-
tients [8], subjected to treadmill exercise [6], resisted 
load breathing [7] and methacholine provocation [8] 
without alteration in β-endorphin immunoreactivity 
in circulating blood [6, 7], oxygen uptake [6, 7], 
minute ventilation [6–8] and cardiorespiratory para-
meters [6, 7]. Opioid receptors are widely distributed 
throughout central nervous system, including the 
nociceptive system and respiratory centres in brain-
stem [9, 10]. In the receptor binding study of central 
nociceptive system, Baumgartner et al. [10] have 
shown that opioid receptors occur most densely in 
thalamus, basal ganglia, amygdala, cingulate cortex 
and insular cortex. Similar brain structures, i.e. insular 
cortex, anterior cingulate cortex and amygdala, have 
been shown in neuroimaging studies to be strongly 
involved in dyspnoea processing [11]. Von Leupoldt et 
al. [12], who compared dyspnoea and pain processing 
in the same group of participants, have shown, that 
both symptoms share same brain areas. However, 
being a part of limbic system, aforementioned brain 
structures might have been activated due to anxiety 
or fear caused by dyspnoea, rather than dyspnoea 
itself [11, 13]. Furthermore, most of neuroimaging 
studies were performed in small numbers of healthy 
volunteers, whose dyspnoea was triggered by various 
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alveoli [20], however, this is not true for humans. Re-
cent studies have shown, that human lungs have all 
the necessary components of endogenous opioid 
system, i.e. opioid peptides, their precursors, and ap-
propriate proprotein convertases, with corresponding 
opioid receptors located densely in superficial layers 
of trachea and large bronchi on C-fibres and pulmo-
nary neuroendocrine cells (PNEC) [21]. Human opioid 
receptors are also located on submucosal bronchial 
glands and alveolar macrophages [21]. Exact function 
of this local, pulmonary opioidergic system, along 
with PNECs, is unknown, however, it is postulated 
that it might participate in maintaining homeostasis 
of respiratory tract and that its elements can also be 
targeted to treat dyspnoea, specifically to modulate 
peripheral transmission via vagal afferents innervating 
bronchi [21, 22]. 
The antinociceptive effect of opioids associated 
with their action on μ, κ and δ receptors, located in 
the central nervous system (CNS) and in the peripheral 
tissues, can also be beneficial in dyspnoeic patients, 
whose breathing is limited or aggravated by pain 
[9], which is a common, accompanying symptom in 
advanced pulmonary diseases e.g. COPD [23]. On the 
other hand, alleviating pain in given patient might 
reveal full extent of opioids negative influence on 
respiration, previously stimulated by pain [9]. Opi-
oid receptors can also affect cough reflex. Although 
cough is mediated by all subtypes of afferent nerves 
innervating the airways, including opioid receptor-rich 
C-fibres, antitussive opioids act mainly centrally, in 
brainstem cough centres [24].
Clinical practice guidelines  
and meta-analyses
The increasing knowledge of opioid receptors/sys-
tems in respiratory tract, and growing number of RCTs 
demonstrating the positive effect of opioids on respi-
ratory symptoms are reflected in changing palliative 
treatment guidelines. Significant progress has been 
made in recognising opioids as complementary to 
disease-targeted treatment in advanced lung diseases, 
thus opioids are currently recommended in managing 
dyspnoea in advanced diseases of lung and heart by 
a significant number of national and international 
associations, including American College of Chest 
Physicians [25], Global Initiative For Chronic Obs-
tructive Lung Diseases [26] and others [2, 27]. Before 
commencing the treatment, patients should measure 
their dyspnoea on an appropriate scale, such as visu-
al analogue scale or numerical rating scale [2, 25]. 
Dyspnoea intensity should then be regularly reviewed 
during the treatment to assess its effectiveness. Apart 
from pharmacotherapy, patients should also be advi-
sed on other, non-pharmacologic therapies of proven 
efficacy, such as pursed–lip breathing, handheld fans, 
chest wall vibration, neuromuscular electrical stimula-
tion or relaxation [2, 25, 27]. It is prudent to exclude 
other, potentially treatable co–morbidities, such as 
heart failure or gastro-oesophageal reflux, which 
might increase dyspnoea in patients with advanced 
lung diseases. Moreover, it is essential to discuss 
the end-of-life care with patients, explaining its role 
and its limits [25]. Opioids are also recommended in 
treatment of cough, although quality of evidence, 
including cancer–related cough, is low [28].
Recommendations of Association for Palliative 
Medicine of Great Britain and Ireland [29] and meta-a-
nalysis conducted by Yancy et al. [30], both, despite 
low-quality evidence, point to opioids as one of the 
options in the treatment of cough in malignant and 
non-malignant diseases. However, according to guide-
lines [3, 29, 31, 32], opioid treatment trial should be 
proceeded with careful differential diagnosis regar-
ding other causes of cough, which could be treated 
causally e.g. gastro-oesophageal reflux, rhinosinusitis 
or ACE inhibitors. Afterwards, a trial with medications 
with more favourable side-effects profile compared to 
opioids should be conducted, which include demul-
cents, expectorants or sodium cromoglicate inhala-
tions [29, 32]. When this approach fails, opioids or 
opioid derivatives, such as dextromethorphan, could 
be started [29, 32]. Other pharmacotherapy options 
include substances, which suppress cough centrally 
e.g. butamirate, gabapentin, amitriptyline; or peri-
pherally, through their action on afferent nerves e.g. 
levodropropizine, nebulised lidocaine or thalidomide 
[3, 29, 32].
Opioids can be delivered systemically — most 
commonly orally [33]. While all opioids used for re-
spiratory indications can be administered orally, some 
of them, i.e. morphine, oxycodone, fentanyl, can be 
delivered subcutaneously. These opioids can also be 
used intravenously, when there is a need for a fast 
onset of action or when there are contraindications to 
oral or subcutaneous delivery i.e. generalised oedema, 
anasarca, impaired peripheral circulation, coagulation 
disorders, rash or other skin changes, especially its 
infections, nausea, vomiting, and bowel obstruction 
[34, 35]. It is important to modify the dosage accor-
dingly when changing route of drug delivery.
Other therapeutic option is delivering opioids thro-
ugh nebulisation, which seems to be a preferred route 
of drug administration by most palliative patients with 
dyspnoea [35]. Treatment of respiratory disorders by 
delivering drugs locally, via inhalations, is common be-
cause of its advantages, which include achieving high 
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drug concentrations locally with little systemic impact. 
However, there is no consensus among researchers 
whether nebulised opioids act locally, through their 
receptors on PNEC and C–fibres, or systemically, after 
absorption from airways [36]. It is worth underlining, 
that systemic absorption of nebulised morphine, 
delivered by jet nebulisers, is low, approximately 5% 
[37, 38]. Bioavailability of lipophilic fentanyl, encapsu-
lated in liposomes, delivered by jet nebuliser is slightly 
higher — 12% [39]. It is possible to increase bioavaila-
bility of nebulised opioids even further, to nearly 100%, 
by using novel nebulisers targeting pulmonary alveoli, 
both with morphine and fentanyl [40, 41]. However, 
this kind of drug delivery does not differ significantly 
from intravenous route and shares similar side effects 
profile, significantly more burdensome compared to 
opioids delivered to bronchial tree [16]. In vitro studies 
show that opioids, applied locally, can reduce mucus 
production, limit bronchus constriction and release of 
pro-inflammatory mediators [20, 21], suggesting their 
role in maintaining pulmonary homeostasis. It is to no 
surprise when it is postulated that opioids, through 
the interaction with their respective receptors on PNEC 
and innervating them C-fibres, might limit neurogenic 
inflammation and signal generation to CNS [21]. These 
claims seem to be supported by the study of Quigley 
et al. [42], in which adding nebulised morphine to sys-
temic morphine, further decreased dyspnoea intensity 
in cancer patients.
Clinical efficacy of nebulised opioids in dyspnoea 
treatment, most often morphine [43–61], hydromor-
phone [55, 57, 62, 63] and fentanyl [36, 64, 65], was 
studied in different patient populations, i.e. with 
primary or metastatic lung cancer [43, 45, 46, 54–57, 
60, 63, 65], COPD [36, 46, 51, 52], ILD [46, 48, 51, 52] 
and CF [58, 59, 64]. Research, however, is inconclusi-
ve so far. Although initial, low level evidence studies 
suggested their positive effect on dyspnoea, three 
meta-analyses of RCTs [16, 66, 67] did not support 
this notion, thus treating dyspnoea with nebulised 
opioids remain unsupported by national and inter-
national respiratory guidelines [2, 25, 27]. Merely 
one meta–analysis demonstrated positive effect of 
nebulised opioids in treating dyspnoea [15], altho-
ugh this was thanks to one RCT [53]. However, there 
are doubts whether jet nebulisers used in studies so 
far, calibrated mostly for peripheral deposition, were 
appropriate for delivering morphine to respiratory 
tract. Recently, Janowiak et al. [68] published results of 
a RCT, in which morphine was delivered by dosimetric 
nebuliser, calibrated to target large airways, where 
most of the human opioid receptors are located on 
PNEC and C-fibres, which allowed to achieve a signi-
ficant dyspnoea reduction. Nebulised morphine was 
also employed to treat persistent cough, however, its 
positive effect was reported in case studies [69–71] 
and was not verified in RCTs.
Characteristics of selected opioids
According to a Cochrane systematic review, only 
two opioids, delivered systemically, are effective in 
treating dyspnoea: morphine and dihydrocodeine 
[67]. However, these drugs are not safe to use in 
patients with significant renal failure, that is why 
guidelines [2, 72] recommend in this group, a trial 
of opioids, whose metabolites do not accumulate 
in renal failure i.e. fentanyl, oxycodone, methadone 
or hydromorphone. However, apart from fentanyl 
[73–76], these substances were not thoroughly tested 
in this setting. Methadone for dyspnoea was studied 
only after epidural use [77], hydromorphone was 
ineffective [63], whereas oxycodone effectiveness was 
reported in case studies [78, 79]. Regarding cough 
treatment, according to the Cochrane systematic 
review [28], the most effective opioids are morphine, 
codeine and dihydrocodeine — however, the quality 
of evidence is low.
Opioids of step two analgesic ladder
Codeine is a methyl derivative of morphine, 5–10% 
of its dose is metabolised to morphine. Codeine has 
central antitussive activity, as well as weak sedative 
and analgesic effect through its action on μ recep-
tors. Its antitussive and analgesic effect is maintained 
for four to six hours. The maximum dose is 240 mg 
per day, while interval between doses should be no 
less than four hours. It is worth underlining, though, 
that codeine, according to latest evidence, has no 
benefit over dextromethorphan or placebo in cough 
treatment and should be avoided [29, 31]. A low-dose, 
slow-release morphine should be tried instead [29].
Dihydrocodeine (DHC) — is a semi-synthetic 
opioid analgesic, derivative of codeine, formed by 
hydrogenation of double bonds in the main chain of 
the codeine molecule. Dihydrocodeine is used as an al-
ternative to codeine in treating moderate to severe 
pain, dyspnoea, and cough. Its dosage is 60 to 90 mg 
q12h. Daily dose should not exceed 240 mg [34, 80].
Opioids of step three analgesic ladder
Morphine is a pure opioid receptor agonist, binds 
predominantly to μ receptors and, to a lesser extent, 
also to κ and δ receptors. After crossing the blo-
od-brain barrier, morphine and its metabolites, deliver 
a strong analgesic and sedative effect, as well as cause 
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depression of respiratory and cough centres in the 
medulla. It is worth mentioning, that its antitussive 
effect occurs in lower doses than analgesic [29]. Due 
to its hydrophilic properties, morphine does not ac-
cumulate rapidly in CNS, what makes it theoretically 
safer than lipophilic opioids, such as fentanyl, espe-
cially in populations with a high risk of respiratory 
depression [9].
Morphine, delivered orally and parenterally, is the 
opioid of choice in the treatment of dyspnoea. It is 
also indicated in the management of pain, cough, 
dyspnoea and diarrhea. There is no uniform dosing 
schedule of morphine in patients with dyspnoea. 
However “start low and go slow” approach is recom-
mended — mostly because of a lower risk of side ef-
fects. It is worth to emphasise, that sedation is usually 
not observed and there are no reports of respiratory 
depression, if careful morphine titration is instituted 
[2]. Guidelines propose the following morphine dose 
titration scheme in dyspnoea:
1. In opioid-naive patients the typical, initial oral dose 
of immediate-release morphine in non-cancer lung 
diseases is 1.25 to 2.5 mg q4h [2]. However, some 
experts recommend even lower doses of morphine. 
The Canadian Thoracic Society experts in COPD 
[27] guidelines propose to administer initially 0.5 
mg immediate-release morphine syrup q12h. If 
no side-effects are observed for two days, the 
dosage should be increased then to 0.5 mg q4h, 
while awake, for five days. After that period, do-
sage can be increased to 1.0 mg orally q4h, while 
awake, and then increased weekly by 1 mg q4h 
or 25% of the current dose. This approach might 
allow for safer adaptation to lowered hypercapnia 
ventilatory response [9]. Other approach was pre-
sented by Currow et al., who, in a study on chronic 
dyspnoea [81], safely started patients on 10 mg 
daily of sustained-release morphine, increasing 
this dose weekly by 10 mg to a maximum dose 
of 30 mg daily. Study group included COPD, ILD, 
primary and metastatic cancer patients.
2. If dyspnoea develops in a patient previously treated 
with opioid other than morphine or dihydrocode-
ine, discontinuation of therapy and initiation of 
morphine in appropriate dose might be conside-
red [72].
3. In a patient who has previously received morphine 
for pain and developed dyspnoea afterwards, an 
additional dose is required, usually 25–50% of the 
current daily dose, based on dyspnoea severity 
[2, 36]. 
4. When the lowest effective, stable, i.e. unchanged 
for at least two weeks, opioid dose, without signi-
ficant side–effects is reached, immediate-release 
formulations can be changed to sustained-release. 
Typically, dyspnoeic patients achieve full benefit of 
opioid therapy while receiving 30 mg of morphine 
daily, or less [81]. It is worth underlining that ta-
chyphylaxis has not been observed despite several 
months of use [81]. 
5. Rescue doses in episodes of sudden dyspnoea 
exacerbations i.e. breakthrough dyspnoea dose 
could range from 1/10 [72] to 1/6 [82] of the total 
24-hour regular dose or equal 50% of q4h dose [2].
Oxycodone is a pure opioid agonist with affinity 
to μ, κ, and δ receptors, with analgesic and sedative 
effects. Starting dose in opioid-naive patients equals 
10 mg q12h. Other indications for oxycodone, apart 
from dyspnoea, are moderate to severe pain and se-
vere idiopathic restless leg syndrome [14, 83].
Fentanyl is a synthetic opioid analogue with a po-
tency 100 times greater than morphine. It is charac-
terised by a strong affinity to μ opioid receptors and 
a weak affinity to δ opioid receptors. Fentanyl is highly 
lipophilic and easily penetrates the blood-brain bar-
rier, thus it acts rapidly. It accumulates in liver failure, 
however, is well tolerated in kidney failure. The most 
popular formulations are transdermal patches, buccal 
tablets, nasal spray and ampules for either intraveno-
us or subcutaneous injections and subarachnoid or 
epidural infusion. Because of its properties, fentanyl 
has been shown to be useful in breakthrough dysp-
noea [82], especially when delivered transmucosally 
or as nasal spray. Moreover, in a RCT by Simon et al. 
[76], fentanyl buccal tablet, 100–200 μg, provided 
greater and faster dyspnoea relief than immediate-re-
lease morphine.
Adverse effects of opioids
Although opioids delivered via nebulisation have 
limited side effects [16], of which most often reported 
are bitter taste [35–39], cough [44, 46] or dizziness 
[42], this is not the case for parenteral opioids. The 
most common side effects of parenteral opioids inclu-
de nausea, vomiting, sedation, pruritus, hyperalgesia 
and constipation, which is the most frequent one [34]. 
Careful dose titration is essential in the prevention 
of undesirable effects. Furthermore, it is advisable 
to implement prevention measures simultaneously 
with opioid therapy [84], e.g. constipation should be 
prevented through proper diet, laxatives or treatment 
with opioid antagonists, e.g. prolonged-release tablets 
of oxycodone combined with naloxone [34]. 
Chronic opioid use can also worsen obstructive, as 
well as central sleep apnea and reduce CPAP efficacy 
[85]. These negative effects are especially evident, 
when patient is on methadone, opioid doses are high 
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(> 200 mg daily morphine equivalent dose), and when 
opioids are co–administered with benzodiazepines 
[86]. However, evidence is conflicting with some of the 
studies showing improved sleep quality with opioid 
use [86]. Nevertheless, once daily dosing, in the mor-
ning, as in the study conducted by Currow et al. [81], 
seems to have the least influence on sleep quality [87].
Two of the aforementioned opioids, i.e. morphine 
and codeine, can cause significant histamine rele-
ase via mast cells degranulation, whereas histamine 
release by oxycodone and fentanyl is minimal [88]. 
Histamine release results in dilatation of blood vessels 
and, in some patients, might cause urticaria, pruritus 
and bronchospasm. Because of this, opioids, especially 
morphine and codeine, should be avoided in severe 
asthma, or if necessary should be used with caution, 
and their dose should be reduced when asthma exa-
cerbation develops [89, 90]. It is worth to underline, 
that metanalyses of RCTs [15, 16], studying the use 
of parenteral and nebulised opioids in dyspnoea, did 
not report any bronchospasm incident or any other 
serious adverse effect.
Fear of respiratory depression associated with 
opioid use has previously prevented their use in on-
cology and is still feared by medical professionals 
[91–93]. Meanwhile, respiratory depression is a rare 
phenomenon, which occurs in 0.2% of patients [84] 
and is easily avoided by proper dose titration [81]. 
Moreover, respiratory depression in usually proceeded 
by change in mental status and sedation [17]. The 
risk of respiratory depression increases in the elderly, 
obese, in the patients with concomitant cardiac dise-
ases [85], and when opioids are used together with 
other medications, which influence the respiratory 
centres in brainstem [9]. Although, as mentioned 
above, opioids can reduce dyspnoea without causing 
significant changes in blood gas levels [15, 16], there 
are still concerns whether patients with hypercapnia 
can be safely treated with opioids [27]. Ekstrom et 
al. [94] published a prospective study on 2249 COPD 
patients starting long-term oxygen therapy in Sweden 
and showed that treatment with low-dose opioids 
for dyspnoea, i.e. ≤ 30 mg daily [81] is not associated 
with higher mortality, even in patients with concurrent 
hypercapnia. Nevertheless, chronic opioid use in hy-
percapnic patients should be cautious and, possibly, 
associated with blood gas monitoring. However, most 
guidelines do not address this issue. It is worth men-
tioning, that in the aforementioned study [94] higher 
opioid doses, i.e. > 30 mg daily, were associated with 
higher mortality. Similar association between higher 
mortality and opioid use in COPD patients was also 
found in a retrospective study by Vozoris et al. [95]. 
However, the authors of other observational study 
[96], in general Norwegian population, suggest that 
this association is probably caused by greater opioid 
use in patients approaching death. Furthermore, re-
trospective studies conducted among patients at the 
end of life did not show that opioids shorten survival 
[97, 98]. 
Summary
The use of opioids in the treatment of advanced 
lung diseases is related to their analgesic and anti-
tussive properties along with their direct effect on 
dyspnoea, both central and, presumably, local. The 
development of medical knowledge and growing 
clinical experience have especially affected dyspnoea 
treatment guidelines, which now recommend opioids 
as a standard, palliative measure, despite fear of side 
effects among healthcare professionals. The proper 
opioid treatment, i.e. choosing a proper drug, way of 
delivery and dose titration permits safe use of opioids 
in dyspnoea therapy. Opioids can be delivered via 
different routes: orally, subcutaneously, intravenously, 
intranasally, buccally and via nebulisations. The latter, 
despite controversies, if proven efficient in further 
studies, could be a viable route of opioid delivery 
because of its ease of use and limited side effects.
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